Calcium supplement

ApprovedSmall molecule

Eli Lilly

Calcium supplement is one of 103 small molecule programs targeting Physical Activity. It is currently in Approved.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Physical ActivityActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

OsteoporosisActive, not recruiting

HypocalcemiaActive, not recruiting

Physical ActivityPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 1/Phase 2

Active, not recruiting

OsteoporosisApproved

Active, not recruiting

HypocalcemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Calcium supplement

Eli Lilly

Approved

1 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Uloric

Takeda

Preclinical

3 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Lorelco

Sanofi

Preclinical

1 8

Miochol

BBausch Health Americas, Inc.

Preclinical

2 9

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoporosis3 trials

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00670501·1,637 enrolled

Effect of Wii Fit Balance Board Games on Balance in Patients With Osteoporosis Post Mastectomy

Completed·—·N/A·NCT07364279·60 enrolled

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT01753856·69 enrolled

Overweight1 trial

Supplemental Calcium in Overweight People

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00030238·540 enrolled

Physical Activity1 trial

Physical Activity, Calcium, and Bone in Children

Completed·—·Phase 2·NCT00000415·224 enrolled

Hypocalcemia1 trial

The Incidence of Hypocalcemia in Pregnant Women at Siriraj Hospital

Unknown status·SSiriraj Hospital·N/A·NCT06160479·444 enrolled

Postmenopausal Women1 trial

Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00729183·214 enrolled

3 more indications

Chronic Kidney Disease1 trial

Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology

Unknown status·MMinistry of Health, Sri Lanka·Phase 1/2·NCT01624064·200 enrolled

Glucocorticoid1 trial

Glucocorticoid Induced Whole Body Catabolisme

Completed·UUniversity of Aarhus·Phase 2·NCT01762540·19 enrolled

Treatment1 trial

Treatment of Calcium Deficiency in Young Women

Completed·—·Phase 2·NCT00000426·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Calcium supplement. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcium supplement compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcium supplement. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

Calcium supplement

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoporosis3 trials

Overweight1 trial

Physical Activity1 trial

Hypocalcemia1 trial

Postmenopausal Women1 trial

Chronic Kidney Disease1 trial

Glucocorticoid1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News